Lin et al. performed a phase 1 trial of EphA2 CAR-T cells in three EphA2-positive recurrent GBM patients with transient clinical efficacy and initial tolerability at the tested dose level (NCT03423992) (Fig. 3). The gene discussed is EPHA2; the disease is glioblastoma.